Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

OCREVUS® is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features1

OCREVUS® is indicated for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity1 

MoA

OCREVUS®  is a recombinant humanised monoclonal antibody that selectively targets and depletes CD20-expressing B cells1

More

RMS

In RMS, when is highly effective therapy needed? NOW3,4

Find out more about:

OCREVUS® core data in RMS

OCREVUS® OLE data in RMS

PPMS

Which treatment is proven and effective in PPMS? ONLY ONE5

Find out more about:

OCREVUS® study design in PPMS

OCREVUS® efficacy in PPMS

OCREVUS® safety in PPMS 

Safety profile

OCREVUS® was generally well tolerated by RMS and PPMS patients1,2,5

Find out more about:

OCREVUS® Safety Profile

OCREVUS® ADRs

OCREVUS® IRRs

OCREVUS® Warnings and precautions

Dosing

OCREVUS® is dosed every 6 months1

Find out how to:

Dose OCREVUS®

Store OCREVUS®

Prepare OCREVUS®

Administer OCREVUS®

Roche in Neuroscience

Learn about our work, see upcoming events and access helpful materials

Roche in Neuroscience

Meetings in MS

Support materials

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. As OCREVUS® is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

For full details, please refer to the OCREVUS® GB Summary of Product Characteristics or to the  OCREVUS® NI Summary of Product Characteristics.

AE, adverse event; GB, Great Britain; IRR, infusion related reaction; MoA, mode of action; NI, Northern Ireland; OLE, open label extension; PPMS, primary progressive multiple sclerosis; RMS, relapsing multiple sclerosis.

 

References:

  1. OCREVUS® Summary of Product Characteristics (GB and NI). 
  2. Hauser SL et al. N Engl J Med 2017;376(3):221-234. 
  3. Giovannoni G et al. Mult Scler Relat Disord 2016;9 Suppl 1:S5-S48. 
  4. Tintore M. Int MS J 2007;14(1):5-10.
  5. Montalban X et al. N Engl J Med 2017;376(3):209-220.

 


M-GB-00004996
Date of preparation: October 2021